sever
pneumonia
patient
repres
major
concern
physician
high
mortal
morbid
rate
attribut
episod
past
decad
mani
strategi
implement
aim
optim
outcom
patient
sever
lung
infect
state
immunocompromis
sever
pneumonia
relat
multipl
drugresist
infect
may
contribut
sever
hypoxem
respiratori
failur
trigger
septic
shock
fatal
outcom
associ
multipl
organ
dysfunct
syndrom
colon
bacteria
respons
main
coordin
believ
excess
inflammatori
cascad
also
respons
core
immun
reaction
nowaday
antimicrobi
therapi
complet
enough
significantli
reduc
mortal
number
sever
pneumonia
addit
therapi
gc
may
constitut
import
portion
better
resolut
pneumonia
treat
properli
sever
pneumonia
eventu
lead
sever
complic
includ
acut
respiratori
distress
syndrom
ard
sepsi
character
persist
pulmonari
inflamm
alveolarcapillari
disrupt
commonli
affect
critic
ill
patient
estim
mortal
rate
review
recent
report
clarifi
whether
system
corticosteroid
impact
outcom
patient
sever
pneumonia
addit
explor
possibl
explan
role
mechan
corticosteroid
sever
pneumonia
ard
common
frequent
fatal
two
patholog
featur
lung
deriv
pulmonari
fibrosi
sepsi
secondari
pneumonia
primari
etiolog
death
patient
late
ard
day
cytokin
level
tnf
highest
cap
fatal
sever
sepsi
lowest
cap
sever
sepsi
mani
decad
mani
studi
observ
implic
gc
shock
sepsi
reduc
mortal
nevertheless
deal
inconclus
result
begin
accept
administ
highdos
steroid
use
either
methylprednisolon
mgkg
dexamethason
mgkg
divid
dose
day
treat
patient
sever
sepsi
septic
shock
yet
later
highdos
gc
show
possibl
harm
fail
decreas
mortal
enthusiasm
evalu
efficaci
gc
still
becam
topic
howev
low
dose
gc
success
decreas
mortal
rate
sever
metaanalys
confirm
surviv
hemodynam
benefit
concern
use
lowdos
hydrocortison
earlier
clinic
studi
lowdos
methylprednisolon
load
dose
mgkg
follow
mgkg
per
day
earli
phase
postop
ard
show
suppress
fibroprolifer
earli
state
respons
lung
injuri
decreas
crp
improv
outcom
signific
reduct
cytokin
plasma
balf
improv
oxygen
index
decreas
lung
injuri
score
mod
also
state
benefit
gc
late
ard
contrast
highdos
steroid
therapi
associ
increas
mortal
eventu
new
recommend
surviv
sepsi
campaign
ssc
protocol
develop
intern
assess
reduc
mortal
due
septic
shock
summar
key
point
stressdos
gc
therapi
given
septic
shock
blood
pressur
identifi
poorli
respons
fluid
vasopressor
therapi
high
dose
gc
compar
mg
hydrocortison
daili
administ
sever
sepsi
septic
shock
also
suggest
gc
administ
treatment
sepsi
absenc
shock
cytokin
play
import
role
send
signal
cell
cell
within
immun
respons
crucial
role
inflamm
lung
depend
express
complex
group
proinflammatori
mediat
cytokin
respons
sever
pneumonia
close
relat
elev
uncontrol
cytokin
one
cohort
investig
sever
sepsi
cap
follow
organ
dysfunct
mortal
reveal
cytokin
level
elev
happen
subject
cap
wherea
cytokin
concentr
highest
onset
attenu
rapidli
first
day
remain
elev
throughout
first
week
activ
level
proinflammatori
antiinflammatori
cytokin
significantli
uprais
prior
mortal
et
al
studi
demonstr
patient
receiv
gc
concentr
crp
remark
decreas
serum
bal
bronchoalveolar
lavag
recent
studi
also
observ
product
macrophag
inflammatori
monocyt
chemotact
keratinocytederiv
chemokin
kc
interferong
level
superior
suppress
effect
combin
clarithromycin
dexamethason
antiinflammatori
immuneosuppress
process
gc
defin
two
mechan
genom
mechan
nongenom
mechan
prior
mean
directli
dna
bind
transactiv
henc
inactiv
transcript
factor
transrepress
first
ligandactiv
gra
bind
homodim
glucocorticosteroid
respons
element
gre
target
gene
induc
transcript
dna
code
call
transactiv
second
crosstalk
mechan
regul
gene
express
gcligand
gr
upregul
downregul
inflammatori
transcript
factor
protein
nuclear
activ
defin
transrepress
anoth
mechan
gc
signal
membraneassoci
receptor
second
messeng
describ
nongenom
pathway
mode
action
entail
mechan
directli
initi
influenc
gene
express
effect
blunt
inhibitor
gene
transcript
nongenom
mechan
involv
activ
endotheli
nitric
oxid
synthetas
eno
bind
gc
gr
stimul
akt
kinas
lead
eno
activ
nitric
oxidedepend
vasorelax
nitric
oxid
particip
mani
inflammatori
manifest
includ
vasodil
inflammatori
cell
recruit
dysregul
system
inflamm
state
excess
product
proinflammatori
transcript
factor
nuclear
factorkappab
fail
inhibitori
action
antiinflammatori
transcript
factor
gc
receptor
central
pathogenesi
pulmonari
extrapulmonari
organ
dysfunct
within
ard
patient
despit
excel
antiinflammatori
efficaci
use
gc
therapeut
often
restrain
due
two
major
drawback
first
longterm
treatment
gc
often
accompani
sever
side
effect
diabet
increas
risk
infect
osteoporosi
hypertens
forth
occurr
gc
resist
also
restrict
mani
gcbase
therapi
second
reason
normal
condit
hypothalamicpituitaryadren
hpa
axi
regul
secret
gc
suppress
hpa
axi
adren
failur
may
result
inadequ
gc
activ
regul
inflammatori
respons
sever
ill
patient
studi
investig
relationship
adren
function
sever
pneumonia
increas
serum
cortisol
concentr
report
shown
link
sever
mortal
cap
poor
prognosi
ard
patient
frequent
associ
failur
activ
gr
suppress
transcript
inflammatori
cytokin
time
peripher
gener
stimul
hpa
axi
level
independ
synergist
thu
indirectli
suppress
immun
respons
alter
grbind
affin
also
demonstr
sever
sepsi
septic
shock
describ
annan
et
al
patient
classifi
circi
baselin
serum
cortisol
level
increas
serum
cortisol
cosyntropin
stimul
also
suggest
metyrapon
test
might
use
tool
diagnosi
circi
current
surviv
sepsi
campaign
recommend
initi
hour
intraven
hydrocortison
therapi
consid
septic
shock
patient
adequ
respond
fluid
resuscit
vasopressor
agent
sever
pneumonia
one
lead
caus
intens
care
unit
icu
admiss
among
septic
patient
incid
pneumonia
increas
age
septic
shock
insuffici
antibiot
treatment
respiratori
failur
acut
lung
injuri
complex
factor
relat
poor
prognosi
use
gc
debat
past
year
earlier
pioneer
weitzman
berger
review
clinic
trial
design
studi
report
gc
use
bacteri
infect
begin
previou
decad
highdos
gc
gener
accept
practition
metaanalys
found
benefit
highdos
gc
sepsi
septic
shock
follow
year
anoth
metaanalys
found
benefit
long
durat
lowdos
gc
innov
treatment
gc
sever
pneumonia
emerg
septic
shock
field
initi
marik
et
al
investig
differ
placebo
lowdos
hydrocortison
mgkg
group
contrast
role
highdos
gc
mean
sd
dose
iv
methylprednisolon
mg
day
assess
et
al
demonstr
gc
decreas
system
lung
inflammatori
respons
bal
neutrophil
count
crp
mechan
ventil
patient
despit
provid
benefit
studi
lack
sampl
size
notic
use
broad
spectrum
antibiot
may
attenu
inflammatori
respons
alveolar
cell
allevi
mechan
ventilationinduc
lung
injuri
seen
vitro
mice
experi
use
gc
consist
debat
howev
use
stressdos
lowdos
gc
patient
septic
shock
improv
hemodynam
function
provid
surviv
benefit
henc
becom
turn
point
low
dose
gc
administ
success
preliminari
sepsi
complic
sever
cap
show
benefit
decreas
mortal
mechan
ventil
use
length
stay
although
studi
show
benefici
effect
gc
likewis
previou
studi
small
number
particip
may
bias
efficaci
treatment
investig
rejuven
enthusiasm
evalu
lowdos
gc
treatment
patient
sever
pneumonia
confirmatori
potenti
benefit
includ
surviv
advantag
reduc
number
organ
system
failur
length
icu
durat
mechan
ventil
other
show
benefit
two
studi
end
result
contradict
even
increas
accompani
advers
effect
snijder
et
al
studi
perform
cap
hospit
patient
show
mg
prednisolon
day
placebo
along
antibiot
show
differ
clinic
outcom
declin
crp
level
faster
attenu
fever
even
lead
late
failur
result
show
frequent
hyperglycemia
versu
p
well
superinfect
occur
versu
p
one
patient
placebo
group
develop
fungal
infect
treat
hydrocortison
discord
result
snijder
et
al
regard
inclus
patient
nonsever
pneumonia
result
higher
rate
advers
effect
advers
effect
may
occur
due
resist
antibiot
gc
incid
rebound
inflamm
initi
suppress
gc
becom
import
issu
context
gc
inhibit
cytokin
inflammatori
mediat
acceler
bacteri
infect
harm
host
howev
use
gc
also
bring
great
influenc
immun
function
macrophag
granulocyt
main
cell
host
defens
bacteria
assumpt
rebound
inflamm
detect
higher
crp
prednisolon
group
week
initi
declin
first
week
like
indic
fact
gc
confer
benefit
earlier
whether
mechan
cytokin
suppress
activ
adrenerg
amelior
rel
adren
insuffici
precaut
use
investig
includ
suscept
infect
mention
earlier
studi
publish
earlier
impress
mega
dose
gc
use
either
methylprednisolon
mgkg
dexamethason
mgkg
divid
day
singl
bolu
dose
hereaft
studi
obtain
indic
harm
dramat
increas
mortal
highdos
gc
treatment
sepsi
final
low
dose
gc
mgday
use
success
sepsi
studi
nowaday
recommend
use
gc
septic
shock
administr
mgday
hydrocortison
underli
hypothes
success
lowdos
gc
dose
attenu
inflammatori
respons
improv
vasopressor
respons
peripher
vessel
increas
mean
arteri
pressur
system
vascular
resist
boost
innat
immun
patient
septic
shock
coagul
disord
secondari
infect
main
reason
lowdos
gc
recommend
two
larg
trial
therefor
physician
revers
shock
improv
surviv
gc
shown
prospect
doubleblind
studi
report
keh
et
al
fact
kind
strategi
could
also
work
sever
cap
howev
durat
therapi
like
day
week
slow
progress
decreas
dose
studi
meijvi
et
al
gc
administ
daili
day
addit
studi
yildiz
et
al
gc
administ
continu
infus
day
addit
studi
confalonieri
et
al
gc
administ
approxim
day
contrast
analysi
result
salluh
et
al
continu
oral
show
improv
clinic
outcom
moreov
also
indic
rebound
inflamm
pandem
influenza
part
season
pandem
patient
result
deterior
outcom
risk
quickli
progress
refractori
hypoxemiain
need
mechan
ventil
thu
frequent
complic
sever
pneumonia
ard
mod
treatment
assess
use
gc
human
avian
influenza
limit
lack
case
gc
use
clinic
manag
patient
associ
ard
hong
kong
vietnam
indonesia
thailand
regard
confound
factor
evid
show
benefici
therapi
gc
patient
later
anim
studi
conduct
regard
gc
use
avian
influenza
efficaci
dexamethason
potent
longlast
glucocorticoid
respons
inhibit
develop
acut
respiratori
syndrom
associ
virusinduc
ard
mice
carter
review
articl
conclud
confound
factor
fact
larg
random
clinic
trial
conduct
possibl
gain
conclus
gc
may
take
effect
given
low
dose
administ
suffici
time
day
sinc
outbreak
minor
patient
might
lead
rapidli
progress
pneumonia
follow
acut
lung
injuri
ali
respiratori
distress
syndrom
ard
gc
often
set
adjuv
therapi
besid
antivir
therapi
measur
attempt
suppress
damag
caus
immun
respons
burnbuisson
et
al
found
earli
cours
gc
median
initi
dose
mg
equival
hydrocortison
per
day
median
patient
influenza
pneumonia
associ
ard
may
hazard
higher
mortal
like
superinfect
benefici
effect
improv
lung
injuri
score
multipl
organ
dysfunct
score
low
mortal
rate
report
quisp
laim
et
al
prolong
lowtomoder
dose
gc
patient
sever
ard
receiv
methylprednisolon
mgkgday
other
receiv
hydrocortison
mgday
durat
day
better
clinic
outcom
also
provid
kudo
et
al
gc
togeth
earli
administr
antivir
agent
pneumonia
wheez
possibl
without
wheez
due
may
prevent
patient
progress
sever
pneumonia
addit
low
dose
methylprednisolon
infus
stress
dose
h
rescu
therapi
day
also
show
wean
ecmo
invas
mechan
ventil
gradual
reduc
crp
level
procalcitonin
level
other
studi
associ
signific
benefici
therapi
sever
ill
patient
unrespons
treatment
furthermor
lead
rapid
improv
resolut
pulmonari
infiltr
may
decreas
viral
load
contrari
studi
liem
et
al
assum
treatment
methylprednisolon
mgkgday
day
progress
mortal
versu
p
studi
suggest
benefit
improv
symptom
gc
increas
mortal
rate
find
similar
gc
therapi
treatment
avian
influenza
gc
use
influenza
patient
incorpor
higher
mortal
import
influenza
viru
relat
sever
viral
pneumonia
inde
diffus
alveolar
damag
may
develop
high
viral
load
reflect
intens
cytokin
reaction
system
inflamm
suggest
gc
may
play
role
increas
replic
viru
certainli
effect
worsen
symptom
diseas
end
mortal
sinc
outbreak
respiratori
diseas
caus
coronaviru
well
known
sar
quickli
spread
around
part
world
mani
studi
demonstr
empir
gc
therapi
treat
sar
time
urgenc
intern
outbreak
allow
time
efficaci
studi
physician
canada
hong
kong
treat
earliest
patient
intraven
ribavirin
broadspectrum
antivir
activ
follow
empir
gc
therapi
treatment
hien
et
al
confirm
earli
hydrocortison
administr
initi
day
ill
associ
significantli
higher
subsequ
plasma
viral
load
second
third
week
durat
viraemia
may
also
prolong
ho
et
al
recommend
initi
use
puls
methylprednisolon
mgday
efficaci
benefit
reduc
icu
admiss
improv
mechan
ventil
mortal
rate
also
equal
shown
safer
compar
low
dosag
thu
lowdosag
gc
also
provid
better
prognosi
sar
patient
symptom
improv
lung
function
studi
sar
patient
guangzhou
critic
patient
receiv
gc
mean
daili
dose
mg
show
benefici
effect
gc
mortal
shorter
hospit
day
octob
establish
intern
sar
treatment
studi
group
manag
sar
demonstr
optim
treatment
option
deal
sar
systemat
review
report
summari
effect
ribavirin
lopinavir
ritonavir
lpvr
gc
type
ifn
intraven
immunoglobulin
ivig
convalesc
plasma
relat
sarscov
replic
inhibit
vitro
mortal
morbid
sar
patient
effect
ard
adult
patient
pneumocysti
jiroveci
pneumonia
pcp
remain
common
highrisk
opportunist
infect
patient
associ
human
immunodefici
viru
hiv
pcp
contribut
one
common
deadli
infecti
diseas
hivinfect
patient
also
nonhiv
patient
immunosuppress
condit
effect
adjunct
gc
reduc
mortal
morbid
p
jirovecii
pneumonia
hiv
patient
demonstr
number
clinic
trial
metaanalysi
briel
et
al
six
random
clinic
trial
perform
last
decad
demonstr
adjunct
treatment
gc
protect
p
jirovecii
pneumonia
risk
ratio
overal
mortal
adjunct
gc
therapi
confid
interv
month
month
followup
suggest
patient
adjuv
gc
could
prevent
need
mechan
ventil
decreas
mortal
combin
trimethoprimsulfamethoxazol
togeth
gc
primari
agent
prophylaxi
therapi
respond
better
result
patient
hypoxemia
gc
show
benefit
sever
hivrel
condit
adjunct
therapi
pneumocysti
carinii
pneumonia
exist
data
support
use
prednison
mg
per
day
taper
week
manag
sever
p
jirovecii
pneumonia
taper
dose
gc
week
reason
option
cell
restor
also
hypothes
gc
treatment
may
benefit
hiv
infect
reduc
autoimmun
compon
deplet
howev
potenti
side
effect
may
state
immunosuppress
relat
higher
incid
bacteri
infect
herp
simplex
herp
zoster
occurr
potenti
develop
kaposi
sarcoma
seem
relev
whether
risk
factor
pjp
like
evolv
nonhiv
set
immunosuppress
agent
therapi
administ
gc
use
preced
one
frequent
contribut
agent
frequent
observ
pjp
underli
diseas
hematolog
malign
solid
organ
transplant
inflammatori
disord
solid
cancer
patient
brain
tumor
receiv
gc
also
suspect
risk
lack
benefit
increas
risk
factor
pjp
demonstr
high
dose
gc
patient
system
lupu
erythematosu
patient
besid
neg
result
benefici
role
applic
nonhiv
patient
assum
adjunct
high
dose
gc
mg
prednison
daili
equival
improv
recoveri
case
sever
adult
nonhiv
pcp
gc
either
togeth
later
specif
antibiot
therapi
may
reduc
respiratori
complic
quickli
resolv
architectur
distort
hrct
chest
nonhiv
immunocompromis
patient
line
evid
direct
practic
practition
continu
evalu
recogn
patient
potenti
enrol
treatment
prophylaxi
consid
risk
benefit
adjunct
gc
hiv
nonhiv
patient
evid
studi
efficaci
gc
provid
signific
reduct
level
marker
system
inflamm
durat
mechan
ventil
icu
stay
decreas
mortal
gc
also
wide
rang
diminish
releas
cytokin
plasma
level
neutrophil
count
crp
level
serum
bal
even
though
enough
line
evid
suggest
gc
consid
adjunct
treatment
due
harm
effect
still
unknown
clinic
outcom
consid
whether
respond
gc
ineffect
effect
harm
influenc
drug
dosag
durat
administr
summar
low
moder
dosag
gc
provid
benefici
outcom
potenti
benefit
effect
gc
administr
may
diminish
discontinu
treatment
preced
slow
taper
may
lead
rebound
inflamm
notic
increas
crp
valu
better
understand
interact
system
gc
immun
respons
necessari
recommend
use
treatment
sever
pneumonia
result
new
studi
alreadi
progress
publish
seem
reason
think
patient
could
benefit
use
gc
patient
sever
pneumonia
certain
etiolog
adren
insuffici
develop
septic
shock
poor
respons
resuscit
maneuv
liquid
perfus
pressor
amin
suggest
futur
studi
pay
attent
enrol
standard
treatment
regimen
includ
time
dosag
formul
durat
length
taper
